Last Updated: 16 Sep 2024
Executive Summary
Arcutis Biotherapeutics Inc. (ARQT) is a clinical-stage biopharmaceutical company specializing in developing and commercializing treatments for dermatological diseases. With a market capitalization of $1.25 billion, ARQT has been experiencing strong quarterly revenue growth of 4.95% year-over-year. However, the company remains unprofitable, with a trailing twelve-month (TTM) net loss of $178.3 million and a TTM diluted EPS of -$2.07.
Company Overview
Headquartered in Westlake Village, California, Arcutis Biotherapeutics focuses on developing innovative therapies for severe and chronic dermatological conditions, including eczema, psoriasis, and acne. The company's pipeline includes several promising drug candidates in various stages of clinical development.
Fundamental Analysis
Financial Performance:
Revenue TTM: $132.1 million
Gross Profit TTM: $29.3 million
Net Loss TTM: $178.3 million
Diluted EPS TTM: -$2.07
Key Metrics:
Price-to-Sales Ratio TTM: 9.44
Price-to-Book Ratio: 6.68
EV-to-Revenue: 8.26
EV-to-EBITDA: -2.04
Technical Analysis
Latest Stock Price: $10.66
52-Week High: $13.17
52-Week Low: $1.76
50-Day Moving Average: $9.91
200-Day Moving Average: $8.03
Short Term Outlook
The technical analysis suggests that ARQT may face short-term resistance at its 50-day moving average of $9.91. However, the stock has been trending above its 200-day moving average of $8.03, indicating potential support.
Long Term Outlook
Arcutis Biotherapeutics has a promising pipeline of drug candidates with the potential to address unmet medical needs in dermatology. If successful in clinical trials and commercialization, these therapies could drive long-term revenue growth and profitability for the company.
Analyst Recommendations
According to the latest analyst consensus, ARQT has received the following ratings:
Strong Buy: 1
Buy: 4
Hold: 1
Sell: 0
Strong Sell: 0
The analyst target price for ARQT is $18.57, representing a potential upside of approximately 74% from the current stock price.
